RECK in Adverse Cardiac Remodeling and Heart Failure
RECK 在不良心脏重构和心力衰竭中的应用
基本信息
- 批准号:10655310
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Age YearsAngiotensin IIAngiotensinsAortic Valve StenosisBiochemicalCardiacCardiac MyocytesCaringCessation of lifeCharacteristicsChronicComplexCongestive Heart FailureCoupledDataDependovirusDevelopmentDiseaseDisintegrinsEpidermal Growth Factor ReceptorFibroblastsFibrosisFunctional disorderGPI Membrane AnchorsGene DeletionGeneticGoalsHealthcare SystemsHeartHeart HypertrophyHeart failureHistologicHospitalizationHumanHypertensionHypertrophyIn VitroInflammation MediatorsInflammatoryInfusion proceduresInterventionLeft Ventricular HypertrophyMapsMatrix MetalloproteinasesMediatorMedicareMembraneMetalloproteasesMolecularMorbidity - disease rateMusMyocardialPathogenesisPatientsPharmacological TreatmentPlayPreventionPrevention strategyProcessProfibrotic signalProteinsPublic HealthPublishingReportingRepressionRoleSatellite VirusesSecondary toSerotypingSignal TransductionStructureTestingTransgenic OrganismsUnited States Department of Veterans AffairsVeteransWild Type Mouseaorta constrictioncardiac magnetic resonance imagingcardioprotectioncoronary fibrosiscostcysteine rich proteinexperienceglycoprotein 130hemodynamicshospital readmissionimprovedimproved outcomein vivolifetime riskmigrationmortalitynew therapeutic targetnovelnovel therapeutic interventionolder patientoverexpressionpharmacologicpressurepreventpromoterprotective effecttherapeutic genetreatment strategy
项目摘要
According to the US Department of Veterans Affairs, heart failure (HF) and associated complications
are one of the main reasons for hospital readmissions and death in the Veterans Healthcare System. In fact,
above 40 years of age, the lifetime risk of developing HF is 1 in 5. Readmissions for HF occur within 30 days
of discharge in 20% of patients older than 65 in the Medicare and Veterans. Together, these healthcare
systems incurred nearly $37.2 billion for HF care. A substantial number of patients develop severe left
ventricular hypertrophy (LVH) secondary to pressure overload (e.g., hypertension, aortic valve stenosis), and
experience episodic severe congestive HF, hospitalization, and increased mortality.
The mechanisms of HF are complex and include local and systemic neurohormonal changes and
hemodynamic overload. RECK (Reversion Inducing Cysteine Rich Protein with Kazal motifs) is a unique
membrane-anchored protein that inhibits many of the mediators responsible for adverse cardiac remodeling,
including MMPs (matrix metalloproteinases), ADAMs (A Disintegrin and Metalloproteinase), EGFR, and
inflammatory mediators. Our published reports demonstrated that angiotensin (Ang)-II, a critical mediator of
hypertension-induced adverse cardiac remodeling, suppresses RECK in vivo. Moreover, Ang-II suppressed
RECK and induced MMP activation and cardiac fibroblast migration in vitro, effects that were reversed by the
ectopic overexpression of RECK. Our preliminary data show that pressure overload (PO) by transverse aortic
constriction (TAC) suppresses RECK and increases MMP activation in a wild type mouse heart. While mice
with inducible cardiomyocyte-specific RECK gene deletion spontaneously develop cardiac hypertrophy and
fibrosis, and these effects are exacerbated by PO by TAC. In contrast, cardiomyocyte-specific RECK
overexpression inhibits PO-induced hypertrophy, fibrosis and contractile dysfunction. Importantly, RECK
expression is reduced in both hypertrophied (aortic stenosis) and failing human hearts of non-ischemic origin.
Based on these critical and novel preliminary data, our central hypothesis is that reversing RECK
suppression or enhancing its expression in the heart will blunt PO-induced adverse structural remodeling and
progression to HF by targeting pro-hypertrophic and pro-fibrotic mediators. Our long-term goals are to
understand the molecular mechanisms underlying the pathophysiology of myocardial hypertrophy and its
transition to HF, and to identify novel therapeutic target(s) for intervention and treatment. Our immediate
goals are to better characterize the cardioprotective role of RECK in inhibiting the pathogenesis of PO-induced
adverse cardiac remodeling and HF development, and to develop an interventional strategy to induce its
expression in the heart. To test our central hypothesis, three specific aims are proposed:
In Aim 1, we will (a) Elucidate the impact of RECK deletion in a conditional cardiomyocyte-specific
manner on spontaneous development of myocardial hypertrophy, fibrosis and dysfunction, and (b) determine
whether RECK deletion exacerbates PO-induced adverse remodeling. In Aim 2, we will determine whether
inducible cardiomyocyte-specific RECK overexpression will prevent the development of or reverse established
PO-induced adverse cardiac remodeling and dysfunction, and progression to HF. In Aim 3, we will determine
whether ectopic overexpression of RECK using an AAV9-based gene therapeutic approach will prevent the
development of or reverse established PO-induced adverse cardiac remodeling and HF.
Thus, our proposed genetic and gene therapeutic approaches will (i) delineate the fundamental
role of RECK in cardiac structure and function, (ii) characterize its role as a critical anti-hypertrophic
and anti-fibrotic mediator in PO, and (iii) demonstrate that its induction in the heart is a novel
therapeutic approach to blunt progression of adverse structural and functional remodeling to heart
failure.
根据美国退伍军人事务部,心力衰竭(HF)和相关并发症
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chandrasekar Bysani其他文献
Chandrasekar Bysani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chandrasekar Bysani', 18)}}的其他基金
Role of novel RNA binding protein LARP6 in alcoholic cardiomyopathy
新型RNA结合蛋白LARP6在酒精性心肌病中的作用
- 批准号:
10593688 - 财政年份:2023
- 资助金额:
-- - 项目类别:
RECK in Adverse Cardiac Remodeling and Heart Failure
RECK 在不良心脏重构和心力衰竭中的应用
- 批准号:
10368301 - 财政年份:2022
- 资助金额:
-- - 项目类别:
TRAF3IP2 in Adverse Cardiac Remodeling and Heart Failure
TRAF3IP2 在不良心脏重塑和心力衰竭中的作用
- 批准号:
10266002 - 财政年份:2018
- 资助金额:
-- - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Role of Angiotensin II in Bladder Dysfunction
血管紧张素 II 在膀胱功能障碍中的作用
- 批准号:
10707997 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Regulation of nuclear calcium and ROS by Angiotensin II in heart cells. Régulation du calcium et ROS nucléaires par l'angiotensine II dans les cellules cardiaques.
血管紧张素 II 对心脏细胞中核钙和 ROS 的调节。
- 批准号:
RGPIN-2016-04414 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
Role of Angiotensin II in Bladder Dysfunction
血管紧张素 II 在膀胱功能障碍中的作用
- 批准号:
10555926 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Regulation of nuclear calcium and ROS by Angiotensin II in heart cells. Régulation du calcium et ROS nucléaires par l'angiotensine II dans les cellules cardiaques.
血管紧张素 II 对心脏细胞中核钙和 ROS 的调节。
- 批准号:
RGPIN-2016-04414 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Operating Grants
Intratubular Angiotensin II and AT1a Receptors in The Proximal Tubules: Roles in Hypertension and Kidney Injury
近曲小管中的管内血管紧张素 II 和 AT1a 受体:在高血压和肾损伤中的作用
- 批准号:
10164776 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Novel Roles of Mitochondrial Angiotensin II in The Proximal Tubule of The Kidney
线粒体血管紧张素 II 在肾近端小管中的新作用
- 批准号:
10251271 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Protection and organ injury by angiotensin II treatment for septic shock
血管紧张素II治疗感染性休克的保护作用和器官损伤
- 批准号:
20K09284 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




